chromosome 1 open reading frame 105Genealiases: []
Q-omics provides the consensus-scored C1orf105 profile across patient tissues and cancer cell-line models. C1orf105 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C1orf105 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, C1orf105 RNA expression shows 11,900 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where C1orf105 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf105 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf105 survival associations across molecular data types. C1orf105 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf105 RNA expression–survival associations across cancer types. High C1orf105 expression shows unfavorable associations in KIRP, LUAD, HNSC, BRCA and CESC, but favorable associations in ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C1orf105 RNA expression.
This table summarizes C1orf105 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf105. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf105 shows lower tumor expression in HNSC and higher tumor expression in COAD, KIRC, LIHC, LUAD and BRCA. The COAD box plot shows higher C1orf105 RNA expression in tumor versus normal tissue (log2 FC = +0.614, t-test p < 0.001).
This table shows molecular features associated with C1orf105 in patient tissues and cancer cell lines. In patient samples, C1orf105 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf105 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
